|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase (ALR2), a NADPH-dependent aldo-keto reductase (AKR), is widely distributed in mammalian tissues and has been implicated in complications of diabetes, including diabetic nephropathy.
|
10944187 |
2000 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
|
10997684 |
2000 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
|
11422753 |
2001 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
|
12542725 |
2003 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aldose reductase and sorbitol dehydrogenase protein levels in the patients with diabetic nephropathy were significantly increased in PBMCs cultured in high-glucose conditions.
|
16644704 |
2006 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
|
11703436 |
2001 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another pathway relevant to diabetic nephropathy is polyol pathway, where glucose is reduced to sorbitol by aldose reductase.
|
11841617 |
2002 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As AKR1B1 is located on 7q35, where we have previously reported linkage to diabetic nephropathy in Pima Indians, this study examined the association of AKR1B1 variants with diabetic nephropathy in this population.
|
16620264 |
2006 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between DN and two DNA sequence variants in the promoter region of the AR gene implicates the polyol pathway in the development of kidney complications in Type 1 diabetes mellitus.
|
10746480 |
2000 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
|
15270790 |
2004 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Autoimmune hypoglycemia in a type 2 diabetic patient with anti-insulin and insulin receptor antibodies.
|
14694017 |
2004 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study strongly suggests that multiple roles for aldose reductase may give it a more complex place in diabetic nephropathy than is currently recognized.
|
12166624 |
2002 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the results of our association study in Caucasian patients with Type II diabetes do not support the hypothesis that the 5'-ALR2 polymorphism in the aldose reductase gene contributes to susceptibility to diabetic nephropathy.
|
10027585 |
1999 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multiple metabolic pathways of DKD have been evaluated with varying success; including mitochondrial function, reactive oxygen species, NADPH oxidase (NOX), transcription factors (NF-B and Nrf2), advanced glycation, protein kinase C (PKC), aldose reductase, JAK-STAT, autophagy, apoptosis-signaling kinase 1 (ASK1), fibrosis and epigenetics.
|
31154867 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes: response to Wang et al.
|
14694018 |
2004 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust and specific inhibition of aldose reductase might be an effective strategy for the prevention and treatment of diabetic nephropathy.
|
21267539 |
2011 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Significant differences were found between AR rs759853 polymorphism and susceptibility of DN from both type 1 and type 2 diabetes in all genetic models (allele contrast, OR = 1.37, CI (1.18, 1.59), P < 0.0001; additive model, OR = 1.78, CI (1.25, 2.53), P = 0.01; recessive model OR = 1.33 CI (1.08, 1.63), P = 0.008; dominant model, OR = 1.52, CI (1.26, 1.84), P < 0.0001; codominance model OR = 1.30 (1.15, 1.47), P < 0.0001).
|
25885804 |
2015 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The -106C>T polymorphism in the promoter region of the aldose reductase (AR) gene has been shown to be associated with the susceptibility to diabetic nephropathy in type 2 diabetes, but the findings regarding the occurrence of diabetic retinopathy are conflicting.
|
16545977 |
2006 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 5' -ALR2 dinucleotide repeat polymorphism is associated with the development of diabetic nephropathy in Southern Chinese with Type 2 diabetes.
|
11874426 |
2002 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C-106T polymorphism in the AR gene is a risk factor for development of diabetic nephropathy in type 2 diabetes in patients with poor glycaemic control.
|
15637423 |
2005 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study therefore, was to investigate the relationship between the aldose reductase gene and type 2 diabetic microvascular complications such as diabetic nephropathy and retinopathy.
|
11796181 |
2002 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the possible beneficial effects of 1-acetyl-5-phenyl-1H-pyrrol-3-ylacetate (APPA), an aldose reductase inhibitor, on DN.
|
28802633 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate whether high glucose induces aldose reductase (AKR1B1) expression through NFkappaB, which may contribute to the pathogenesis of diabetic nephropathy.
|
18325349 |
2008 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The C-106T polymorphism in the AR gene is a risk factor for development of diabetic nephropathy in type 2 diabetes in patients with poor glycaemic control.
|
15637423 |
2005 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data suggested that epalrestat has protective effects on DN, and the inhibition of aldose reductase and the modulation of polyol pathway in nephritic cells be a potentially therapeutic strategy for DN.
|
29930278 |
2019 |